Developer docs
API playgroundTry for free, no card

Search company profiles

Relation Therapeutics

Full company profile

uuid0000he5

Namestring
Relation Therapeutics
Legal namestring
Relation Therapeutics Limited
Websiteurl
relationrx.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Relation Therapeutics is a London-based biotechnology company founded in January 2020 that develops its Lab-in-the-Loop platform, an integrated system combining single-cell and spatial multi-omics from patient tissue, perturbational functional assays, and active-graph machine learning to identify and validate therapeutic targets with genetic evidence before they enter expensive clinical development. Its proprietary Osteomics asset is described as the world's largest functional single-cell bone atlas, generated from patient-derived samples and deeply characterized across genomics, proteomics, imaging and clinical phenotype data, and underpins the company's primary indication in osteoporosis alongside expanding programs in immunology/atopic disease (with Novartis) and fibrosis/osteoarthritis (with GSK). The company serves large pharmaceutical partners through milestone-based strategic collaborations structured with upfront payments, R&D funding and downstream royalties, exemplified by the December 2025 Novartis deal ($55M upfront, up to $1.7B in milestones) and the November 2024 GSK collaborations ($15M equity, up to $300M). A January 2026 collaboration with Deerfield Management adds a complementary company-formation model in which Relation and Deerfield will create new ventures around discovered targets.

The business is pre-revenue with no approved products; total capital raised is approximately $86M across a $25M seed (June 2022, co-led by DCVC and Magnetic Ventures), a $35M seed-2 (March 2024, co-led by DCVC and NVentures) and a further $26M (December 2025, with Novartis participating). Compute infrastructure is anchored by preferred access to NVIDIA's Cambridge-1 supercomputer, and the team is led by a CEO (David Roblin) with 11 prior approved medicines across Pfizer, Summit and the Francis Crick Institute, a CTO (Lindsay Edwards) who founded GSK's first Data Science group, and a President of Drug Discovery (Dave Powell) previously CSO at LifeArc.

Short descriptiontext

Relation Therapeutics is a London-based biotech that uses its Lab-in-the-Loop platform — combining single-cell multi-omics from patient tissue with active-graph machine learning — to discover and validate genetically-supported drug targets for osteoporosis, immunology and metabolic disease, partnering with large pharma on milestone-based collaborations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, single-cell multi-omics, target identification platform, biotechnology drug development, machine learning drug discovery
Industry6 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery / Biopharma R&D Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Strategic Pharma Partnerships
TypeLicensing Royalties
Description

Relation generates revenue through milestone-based collaboration agreements with pharmaceutical companies. Partners pay upfront fees, research funding, and development milestones, with potential royalty payments on net sales of approved products. Example: Novartis partnership includes $55M upfront and up to $1.7B in milestone payments plus tiered royalties.

pharmaceutical-technology.com
2Technology Platform Licensing
TypeProfessional Services
Description

The company leverages its AI-powered drug discovery platform to identify and validate therapeutic targets for partners, generating revenue through co-development arrangements and target validation services.

relationrx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Relation Therapeutics operates an AI-powered Lab-in-the-Loop drug discovery platform that integrates single-cell multi-omics analysis directly from patient tissue, functional assays, and machine learning to identify and validate therapeutic targets. The platform is anchored by Osteomics, the world's largest functional single-cell bone atlas, and is commercialized through milestone-based strategic partnerships with large pharmaceutical companies. The company focuses on bone disease (osteoporosis), immunology/atopic diseases, and metabolic disease, leveraging proprietary patient-derived data and high-performance compute infrastructure.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Drug targets with genetic validation are 2.6 times more likely to succeed in clinical trials
+1 more record
Product overview1 text field

Relation Therapeutics operates as an end-to-end biotech developing transformational medicines with technology at its core. The company's primary offering is the Lab-in-the-Loop Platform—an AI-powered drug discovery system that combines machine learning with multi-omic data from patient tissue to identify and validate therapeutic targets. This platform is underpinned by Osteomics, the world's largest functional single-cell bone atlas, and integrates single-cell analysis, genomics, spatial transcriptomics, and computational approaches. The company focuses on bone disease (osteoporosis), immunology, and metabolic diseases, with programs spanning from target identification through clinical translation.

Product and service3 records
1Lab-in-the-Loop Platform
CategoryAI Drug Discovery Platform
Description

AI-powered drug discovery platform that seamlessly integrates single-cell multi-omics analysis, functional assays, and machine learning to identify causal genes and validate therapeutic mechanisms for pharmaceutical partners. Licensed to large pharma companies through milestone-based strategic collaborations.

2Osteomics
CategoryProprietary Data Asset / Therapeutic Atlas
Description

Proprietary functional single-cell bone atlas developed from patient-derived samples, providing deeply characterized single-cell, spatial omics, imaging, genomics, proteomics, and clinical phenotype data to enable target identification for osteoporosis and bone-related diseases.

3Multi-Omic Patient Data Integration Service
CategoryMulti-Omic Data Service
Description

Technology service that generates and analyzes human genetics and proprietary omics data directly from patient tissue to understand genetic basis of clinical phenotypes and build rich maps of disease biology for novel target discovery, offered as part of strategic collaborations with pharmaceutical partners.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-01
Description

Relation uses Genomics' Mystra AI platform, a conversational AI platform for drug target discovery and validation using large-scale human genetics data. Mystra leverages what Genomics describes as the world's largest genotype-phenotype database compiled from more than 45,000 genome-wide association studies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

Strategic collaboration to advance novel therapeutics, with plans to form new companies from discovered drug targets. Combines Relation's target discovery capabilities with Deerfield's development and investment expertise.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-09
Description

Strategic collaboration to discover and develop novel therapeutic targets for atopic diseases. Novartis pays $55M upfront for global development and commercialization rights, with Relation eligible for up to $1.7B in milestone payments plus tiered royalties on net sales. Relation contributes its AI-powered Lab-in-the-Loop platform using multi-omic patient-derived data to generate functional cell atlases for target identification and validation.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

Two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis, including $15M equity investment. The partnerships leverage Relation's AI platform and disease understanding for target identification across neurodegeneration, fibrosis, and RNA biology.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-03-01
Description

NVIDIA provides computational infrastructure including access to Cambridge-1, the UK's most powerful supercomputer, to power Relation's digital biology breakthroughs and AI-driven drug discovery workflows.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-09-01
Description

Grant awarded in September 2020 to support coalition work with Yoshua Bengio, Mila, and Scripps Research to identify COVID-19 therapeutic candidates.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-09-01
Description

Coalition partner in COVID-19 therapeutic candidate identification alongside Relation, Yoshua Bengio, and Scripps Research, supported by Gates Foundation grant.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-09-01
Description

Coalition partner in COVID-19 therapeutic candidate identification alongside Relation, Yoshua Bengio, and Mila, supported by Gates Foundation grant.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with hospitals and partners across the UK and Australia for patient sample collection supporting the Osteomics bone atlas and other programs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration for research partnerships and knowledge sharing in drug discovery and multi-omic technologies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Recursion is a clinical-stage AI-driven drug discovery company combining high-throughput biology, machine learning, and multi-omic data. It directly competes with Relation in using ML-driven platforms to identify and validate novel therapeutic targets for large pharma partners.

TypeDirect peer
Description

Insitro combines machine learning with high-throughput biology and patient-derived data to discover and develop therapeutics. Its platform model of licensing targets and partnering with pharma closely mirrors Relation's Lab-in-the-Loop approach.

3Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed Isomorphic Labs applies AI and computational methods to drug discovery, with major pharma partnerships (Novartis, Eli Lilly). It competes with Relation for AI-native drug discovery mandates from top-tier pharma.

TypeDirect peer
Description

Exscientia is an AI-driven precision medicine company applying AI to small molecule drug design and partnered pharma collaborations. It is a comparable AI-native biotech pursuing platform-based pharma partnerships.

TypeDirect peer
Description

BenevolentAI uses AI and knowledge graphs to identify novel drug targets and develop treatments. Its focus on graph-based ML for target discovery aligns closely with Relation's active-graph machine learning approach.

TypeBroad incumbent
Description

Schrödinger provides computational chemistry and physics-based simulation software used across drug discovery. It is a broader, more established player operating in the same computational drug discovery category as Relation's platform.

TypeEmerging player
Description

Atomwise uses AI for small molecule design and has pharma collaborations. It overlaps with Relation in applying ML to drug discovery but is less focused on multi-omic patient-derived target identification.

TypeEmerging player
Description

Owkin applies AI to multi-omic patient data for drug discovery and clinical research. It overlaps with Relation's use of multi-omics and ML but focuses more on federated learning and clinical trial optimization.

TypeEmerging player
Description

Absci combines generative AI with wet-lab validation for biologic drug creation. Its zero-shot wet-lab validation approach is thematically comparable to Relation's lab-in-the-loop philosophy.

10Crush Bio (formerly Cradle)
TypeEmerging player
Description

Cradle uses generative AI for protein engineering. While focused on biologics design rather than target discovery, it is an adjacent AI-driven biotech using ML across wet and dry lab workflows similar to Relation's Lab-in-the-Loop.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Relation Therapeutics

AI Drug Discovery / Biopharma R&D Platformrelationrx.com

Relation Therapeutics is a London-based biotech that uses its Lab-in-the-Loop platform — combining single-cell multi-omics from patient tissue with active-graph machine learning — to discover and validate genetically-supported drug targets for osteoporosis, immunology and metabolic disease, partnering with large pharma on milestone-based collaborations.

What Relation Therapeutics does

Relation Therapeutics is a London-based biotechnology company founded in January 2020 that develops its Lab-in-the-Loop platform, an integrated system combining single-cell and spatial multi-omics from patient tissue, perturbational functional assays, and active-graph machine learning to identify and validate therapeutic targets with genetic evidence before they enter expensive clinical development. Its proprietary Osteomics asset is described as the world's largest functional single-cell bone atlas, generated from patient-derived samples and deeply characterized across genomics, proteomics, imaging and clinical phenotype data, and underpins the company's primary indication in osteoporosis alongside expanding programs in immunology/atopic disease (with Novartis) and fibrosis/osteoarthritis (with GSK). The company serves large pharmaceutical partners through milestone-based strategic collaborations structured with upfront payments, R&D funding and downstream royalties, exemplified by the December 2025 Novartis deal ($55M upfront, up to $1.7B in milestones) and the November 2024 GSK collaborations ($15M equity, up to $300M). A January 2026 collaboration with Deerfield Management adds a complementary company-formation model in which Relation and Deerfield will create new ventures around discovered targets.

The business is pre-revenue with no approved products; total capital raised is approximately $86M across a $25M seed (June 2022, co-led by DCVC and Magnetic Ventures), a $35M seed-2 (March 2024, co-led by DCVC and NVentures) and a further $26M (December 2025, with Novartis participating). Compute infrastructure is anchored by preferred access to NVIDIA's Cambridge-1 supercomputer, and the team is led by a CEO (David Roblin) with 11 prior approved medicines across Pfizer, Summit and the Francis Crick Institute, a CTO (Lindsay Edwards) who founded GSK's first Data Science group, and a President of Drug Discovery (Dave Powell) previously CSO at LifeArc.

Relation Therapeutics firmographics

Firmographics
Name
Relation Therapeutics
Legal name
Relation Therapeutics Limited
Website
https://relationrx.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
101–250 employees
Short description
Relation Therapeutics is a London-based biotech that uses its Lab-in-the-Loop platform — combining single-cell multi-omics from patient tissue with active-graph machine learning — to discover and validate genetically-supported drug targets for osteoporosis, immunology and metabolic disease, partnering with large pharma on milestone-based collaborations.
Ownership category
akta.pro rank

Relation Therapeutics industry classification

Industry
Product category
AI Drug Discovery / Biopharma R&D Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)

Keywords

  • AI drug discovery
  • Single-cell multi-omics
  • Target identification platform
  • Biotechnology drug development
  • Machine learning drug discovery

Where Relation Therapeutics is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Relation Therapeutics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Strategic Pharma Partnerships: Relation generates revenue through milestone-based collaboration agreements with pharmaceutical companies. Partners pay upfront fees, research funding, and development milestones, with potential royalty payments on net sales of approved products. Example: Novartis partnership includes $55M upfront and up to $1.7B in milestone payments plus tiered royalties.
  2. Technology Platform Licensing: The company leverages its AI-powered drug discovery platform to identify and validate therapeutic targets for partners, generating revenue through co-development arrangements and target validation services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Relation Therapeutics product offering

Product offering

Core offering

Relation Therapeutics operates an AI-powered Lab-in-the-Loop drug discovery platform that integrates single-cell multi-omics analysis directly from patient tissue, functional assays, and machine learning to identify and validate therapeutic targets. The platform is anchored by Osteomics, the world's largest functional single-cell bone atlas, and is commercialized through milestone-based strategic partnerships with large pharmaceutical companies. The company focuses on bone disease (osteoporosis), immunology/atopic diseases, and metabolic disease, leveraging proprietary patient-derived data and high-performance compute infrastructure.

Product overview

Relation Therapeutics operates as an end-to-end biotech developing transformational medicines with technology at its core. The company's primary offering is the Lab-in-the-Loop Platform—an AI-powered drug discovery system that combines machine learning with multi-omic data from patient tissue to identify and validate therapeutic targets. This platform is underpinned by Osteomics, the world's largest functional single-cell bone atlas, and integrates single-cell analysis, genomics, spatial transcriptomics, and computational approaches. The company focuses on bone disease (osteoporosis), immunology, and metabolic diseases, with programs spanning from target identification through clinical translation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lab-in-the-Loop Platform AI-powered drug discovery platform that seamlessly integrates single-cell multi-omics analysis, functional assays, and machine learning to identify causal genes and validate therapeutic mechanisms for pharmaceutical partners. Licensed to large pharma companies through milestone-based strategic collaborations.
  • Osteomics Proprietary functional single-cell bone atlas developed from patient-derived samples, providing deeply characterized single-cell, spatial omics, imaging, genomics, proteomics, and clinical phenotype data to enable target identification for osteoporosis and bone-related diseases.
  • Multi-Omic Patient Data Integration Service Technology service that generates and analyzes human genetics and proprietary omics data directly from patient tissue to understand genetic basis of clinical phenotypes and build rich maps of disease biology for novel target discovery, offered as part of strategic collaborations with pharmaceutical partners.

Quantifiable outcome

  • Drug targets with genetic validation are 2.6 times more likely to succeed in clinical trials
  • +1 more outcomes

Companies that use Relation Therapeutics

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles1 record

Relation Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Relation Therapeutics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

  • GenomicscoreTechnology or Integration · 1 June 2026Relation uses Genomics' Mystra AI platform, a conversational AI platform for drug target discovery and validation using large-scale human genetics data. Mystra leverages what Genomics describes as the world's largest genotype-phenotype database compiled from more than 45,000 genome-wide association studies.
  • Deerfield ManagementcoreStrategic or Co-development Partner · 7 January 2026Strategic collaboration to advance novel therapeutics, with plans to form new companies from discovered drug targets. Combines Relation's target discovery capabilities with Deerfield's development and investment expertise.
  • NovartisflagshipStrategic or Co-development Partner · 9 December 2025Strategic collaboration to discover and develop novel therapeutic targets for atopic diseases. Novartis pays $55M upfront for global development and commercialization rights, with Relation eligible for up to $1.7B in milestone payments plus tiered royalties on net sales. Relation contributes its AI-powered Lab-in-the-Loop platform using multi-omic patient-derived data to generate functional cell atlases for target identification and validation.
  • GSKflagshipStrategic or Co-development Partner · 1 November 2024Two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis, including $15M equity investment. The partnerships leverage Relation's AI platform and disease understanding for target identification across neurodegeneration, fibrosis, and RNA biology.
  • NVIDIAcoreTechnology or Integration · 1 March 2022NVIDIA provides computational infrastructure including access to Cambridge-1, the UK's most powerful supercomputer, to power Relation's digital biology breakthroughs and AI-driven drug discovery workflows.
  • Bill & Melinda Gates FoundationminorStrategic or Co-development Partner · 1 September 2020Grant awarded in September 2020 to support coalition work with Yoshua Bengio, Mila, and Scripps Research to identify COVID-19 therapeutic candidates.
  • MilaminorStrategic or Co-development Partner · 1 September 2020Coalition partner in COVID-19 therapeutic candidate identification alongside Relation, Yoshua Bengio, and Scripps Research, supported by Gates Foundation grant.
  • Scripps ResearchminorStrategic or Co-development Partner · 1 September 2020Coalition partner in COVID-19 therapeutic candidate identification alongside Relation, Yoshua Bengio, and Mila, supported by Gates Foundation grant.
  • Garvan Institute of Medical ResearchminorStrategic or Co-development PartnerCollaboration with hospitals and partners across the UK and Australia for patient sample collection supporting the Osteomics bone atlas and other programs.
  • Kyoto UniversityminorStrategic or Co-development PartnerAcademic collaboration for research partnerships and knowledge sharing in drug discovery and multi-omic technologies.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Relation Therapeutics competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Recursion is a clinical-stage AI-driven drug discovery company combining high-throughput biology, machine learning, and multi-omic data. It directly competes with Relation in using ML-driven platforms to identify and validate novel therapeutic targets for large pharma partners.
  • Insitro: Insitro combines machine learning with high-throughput biology and patient-derived data to discover and develop therapeutics. Its platform model of licensing targets and partnering with pharma closely mirrors Relation's Lab-in-the-Loop approach.
  • Isomorphic Labs: Alphabet-backed Isomorphic Labs applies AI and computational methods to drug discovery, with major pharma partnerships (Novartis, Eli Lilly). It competes with Relation for AI-native drug discovery mandates from top-tier pharma.
  • Exscientia: Exscientia is an AI-driven precision medicine company applying AI to small molecule drug design and partnered pharma collaborations. It is a comparable AI-native biotech pursuing platform-based pharma partnerships.
  • BenevolentAI: BenevolentAI uses AI and knowledge graphs to identify novel drug targets and develop treatments. Its focus on graph-based ML for target discovery aligns closely with Relation's active-graph machine learning approach.

Broad incumbents

  • Schrödinger: Schrödinger provides computational chemistry and physics-based simulation software used across drug discovery. It is a broader, more established player operating in the same computational drug discovery category as Relation's platform.

Emerging players

  • Atomwise: Atomwise uses AI for small molecule design and has pharma collaborations. It overlaps with Relation in applying ML to drug discovery but is less focused on multi-omic patient-derived target identification.
  • Owkin: Owkin applies AI to multi-omic patient data for drug discovery and clinical research. It overlaps with Relation's use of multi-omics and ML but focuses more on federated learning and clinical trial optimization.
  • Absci: Absci combines generative AI with wet-lab validation for biologic drug creation. Its zero-shot wet-lab validation approach is thematically comparable to Relation's lab-in-the-loop philosophy.
  • Crush Bio (formerly Cradle): Cradle uses generative AI for protein engineering. While focused on biologics design rather than target discovery, it is an adjacent AI-driven biotech using ML across wet and dry lab workflows similar to Relation's Lab-in-the-Loop.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights1 record

Customer concentration

Relation Therapeutics social profiles

Digital presence

Relation Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Relation Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Relation Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Relation Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Relation Therapeutics

What does Relation Therapeutics do?

Relation Therapeutics operates an AI-powered Lab-in-the-Loop drug discovery platform that integrates single-cell multi-omics analysis directly from patient tissue, functional assays, and machine learning to identify and validate therapeutic targets. The platform is anchored by Osteomics, the world's largest functional single-cell bone atlas, and is commercialized through milestone-based strategic partnerships with large pharmaceutical companies. The company focuses on bone disease (osteoporosis), immunology/atopic diseases, and metabolic disease, leveraging proprietary patient-derived data and high-performance compute infrastructure.

Is Relation Therapeutics a public or private company?

Relation Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Relation Therapeutics founded?

Relation Therapeutics was founded in 2020. It employs 101 to 250 people.

Where is Relation Therapeutics based?

Relation Therapeutics is headquartered in London, United Kingdom, in the Europe region.

How does Relation Therapeutics make money?

Two revenue lines are on record. Strategic Pharma Partnerships are the primary driver. The others are technology Platform Licensing.

Who are Relation Therapeutics's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Isomorphic Labs, Exscientia and BenevolentAI. Schrödinger is listed as a broad incumbent. Emerging players are Atomwise, Owkin, Absci and Crush Bio (formerly Cradle).

Does Relation Therapeutics have an API?

No public API is recorded for Relation Therapeutics.

What industry is Relation Therapeutics in?

Relation Therapeutics's product category is AI Drug Discovery / Biopharma R&D Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmExecM&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSKThree pharmaceutical partnerships and transactions were announced this week: Johnson & Johnson agreed to collaborate with Sail Biomedicines, making $785 million in initial payments and gaining an exclusive option to acquire the biotech for up to $2.58 billion, to advance in vivo CAR-T therapies for immune-mediated diseases; Processa Pharmaceuticals acquired Vidya Therapeutics, a clinical-stage biotech developing VT-7208, a next-generation BTK inhibitor, alongside a concurrent $200 million private placement financing led by investors including Bain Capital Life Sciences, RA Capital Management, and Janus Henderson Investors; and Relation Therapeutics entered a strategic collaboration with GSK worth over $110 million in upfront and milestone payments to generate large-scale human cellular perturbation data using Relation's MORGAN foundation model for target discovery.YahooGSK (LSE:GSK) Opens Cambridge Research Hub And Teams Up With Relation TherapeuticsGSK plans to establish a new global R&D centre on the Cambridge Biomedical Campus in the UK, expected to accommodate more than 1,000 scientists and support closer collaboration with nearby research institutions and biotechs. The company has also entered into a research collaboration with Relation Therapeutics that leverages advanced cellular biology models and large-scale data generation. This move positions GSK at the heart of one of Europe's leading life sciences hubs and signals a stronger focus on data-driven and AI-supported drug discovery capabilities.Digital Health NewsGSK & Relation Therapeutics Ink $110 Mn AI Drug Discovery DealGSK has entered into a research collaboration with British biotech firm Relation Therapeutics in a deal valued at up to $110 million, aiming to generate large-scale human cellular datasets and develop AI models to identify potential therapeutic targets for drug development. The partnership builds on a 2024 collaboration focused on fibrotic diseases and osteoarthritis and will support Relation's MORGAN AI platform, which uses automated laboratories to produce high-resolution multi-omic perturbation datasets. The collaboration aligns with GSK's broader strategy to expand AI use in improving drug discovery efficiency and success rates.Longevity.TechnologyRelation builds causal AI for drug discoveryRelation Therapeutics, a London-based biotechnology company, unveiled MORGAN, a foundation model trained on large-scale perturbation datasets from human cellular systems, designed to understand causal biology rather than just associations in disease. The company simultaneously expanded its strategic collaboration with GSK to deepen application of its Lab-in-the-Loop platform across therapeutic discovery. The announcements reflect a broader shift in AI drug discovery toward mechanistic, interventional frameworks that can identify what to perturb to change disease outcomes, rather than merely describing patterns.MarketScreenerGSK, Relation Therapeutics to Collaborate on Human Cellular Perturbation DataGSK plc and Relation Therapeutics are set to collaborate on utilizing human cellular perturbation data to enhance drug discovery and development. This partnership aims to leverage advanced cellular models for better insights into diseases and therapies. The collaboration reflects a strategic effort to innovate within the pharmaceutical sector.MarketScreenerGSK, Relation Therapeutics sign up to $110 million AI drug discovery dealGSK and Relation Therapeutics have entered into a partnership for an AI-driven drug discovery deal valued at $110 million. This collaboration leverages artificial intelligence to accelerate the development of new pharmaceutical treatments. The agreement represents a strategic move by GSK to integrate advanced technology into its research pipeline.MarketScreenerRelation Therapeutics Limited and Glaxosmithkline plc Announce Expanded Collaboration to Generate Large-Scale Human Cellular Perturbation DatasetsRelation Therapeutics Limited and GlaxoSmithKline plc have announced an expanded strategic research collaboration to generate large-scale human cellular perturbation datasets using advanced disease models and experimental systems. Under the agreement, Relation Therapeutics may receive up to $110 million in upfront and success-based milestone payments, with the resulting data used to train foundation models including MORGAN for disease biology research and therapeutic target discovery. The collaboration aims to advance drug discovery by providing new insights into how human cells respond to genetic and pharmacological interventions.BloombergGSK Strikes AI Deal With UK Biotech to Boost Early Pipeline - BloombergGSK Plc agreed to another AI deal with British biotech Relation Therapeutics Ltd. to accelerate drug development. The agreement could pay Relation up to $110 million and will deploy a new foundation model designed to predict how human cells respond to genetic and drug interventions. This collaboration builds on an earlier partnership between the two companies focused on treatments for fibrotic diseases and osteoarthritis.Tech TimesGSK Backs Relation Therapeutics With $110M to Build Biological Data FactoryGSK announced a collaboration with Relation Therapeutics to generate large-scale human cellular perturbation data for training MORGAN, a cellular foundation model. GSK will pay up to $110 million in upfront and milestone payments to Relation for data generation, not for licensing the model. The deal aims to address Phase II trial attrition by improving target selection.European BiotechnologyRelation deepens GSK alliance with $110M dealRelation Therapeutics expanded its GSK collaboration with a deal worth up to $110 million, funding automated labs to generate multi-omics data for training its MORGAN cellular model. The companies did not disclose upfront amounts or target diseases. The deal builds infrastructure for Relation's AI drug discovery platform.